{"gene":"GIP","run_date":"2026-06-10T01:55:21","timeline":{"discoveries":[{"year":1995,"finding":"The human GIP receptor is a 466 amino acid seven-transmembrane domain G-protein coupled receptor that, when stably expressed in fibroblast CHL cells, couples to adenylate cyclase increasing intracellular cAMP (EC50 ~1.29×10⁻¹³ M for human GIP 1-42). The receptor accepts human GIP 1-42 and porcine GIP 1-30 as high-affinity ligands (Kd ~10⁻⁸ M) but shows no response to secretin, glucagon, GLP-1, VIP, PHI, or PACAP. GIP-1-42 stimulation did not increase intracellular calcium in transfected cells.","method":"Molecular cloning from human insulinoma cDNA library, stable transfection into CHL fibroblasts, radioligand binding assay, cAMP accumulation assay, intracellular calcium measurement","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution of receptor in heterologous cells with direct binding and functional cAMP assays, ligand specificity panel, calcium measurement","pmids":["7589426"],"is_preprint":false},{"year":2010,"finding":"GIP (in the presence of insulin) increases LPL gene expression and LPL promoter activity in human adipocytes through a pathway involving PI3-K, PKB, and AMPK-dependent phosphorylation of CREB at Ser133 and nuclear localization of the CREB coactivator TORC2. CREB and TORC2 bind to a cAMP-response element (-II) in the human LPL promoter, and siRNA knockdown of either CREB or TORC2 reduces LPL expression. The cAMP/PKA pathway was not activated by GIP in the presence of insulin.","method":"LPL promoter-luciferase reporter assay in GIP receptor-expressing HEK-293 cells, phosphorylation assays, siRNA knockdown, chromatin immunoprecipitation, co-immunoprecipitation","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (reporter assay, ChIP, siRNA knockdown, co-IP) in a single rigorous study","pmids":["20693566"],"is_preprint":false},{"year":2007,"finding":"A novel GIPR splice variant retaining intron 8 produces a C-terminally truncated GIPR. When co-expressed with wild-type GIPR in transfected cells, this truncated isoform does not produce cAMP in response to GIP but inhibits GIP-induced cAMP production through wild-type GIPR (dominant negative effect), coinciding with reduced wild-type GIPR cell-surface expression. In diet-induced obese mice, the ratio of truncated GIPR to total GIPR mRNA was reduced by ~32%, correlating with increased GIP-induced cAMP and insulin secretion (hypersensitivity).","method":"Transfection of truncated and wild-type GIPR constructs into cells, cAMP assay, cell surface receptor expression assay, RT-PCR in islets from HFD mice, ex vivo islet insulin secretion assay","journal":"American journal of physiology. Endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — heterologous expression with functional assays plus in vivo corroboration, single lab but multiple orthogonal methods","pmids":["17971513"],"is_preprint":false},{"year":2012,"finding":"Each of the N-terminal extracellular Asn residues of the human GIP receptor is glycosylated when expressed in CHO cells. N-glycosylation enhances cell-surface expression and function of the GIPR more strongly than the GLP-1 receptor, primarily by reducing receptor degradation in the endoplasmic reticulum and lengthening receptor half-life. N-glycosylation is required for GIP receptor plasma membrane expression and efficient GIP-potentiated glucose-induced insulin secretion from INS-1 cells. Co-expression of a glycosylation-deficient GIP receptor mutant with wild-type GLP-1 receptor rescues its surface expression, and BRET data indicate formation of a GIP-GLP-1 receptor heteromer.","method":"Site-directed mutagenesis of Asn glycosylation sites, cell-surface expression assays, receptor half-life measurement, INS-1 insulin secretion assay, BRET","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — mutagenesis combined with functional assays (insulin secretion, surface expression) and BRET in a single study","pmids":["22412906"],"is_preprint":false},{"year":2017,"finding":"GIP(3-30)NH2 is a selective, efficacious GIPR antagonist in humans. In COS-7 cells it neither bound nor activated related receptors (GLP-1R, GLP-2R, glucagon R, secretin R, GHRH R). During hyperglycemic clamp in healthy men, co-infusion of GIP(3-30)NH2 reduced GIP-induced insulin secretion by 82% and returned glucose requirements to placebo levels. GIP(3-30)NH2 had no effect alone on glucagon, GLP-1, or lipid parameters.","method":"In vitro receptor binding and cAMP accumulation in transfected COS-7 cells; randomized double-blind crossover hyperglycemic clamp study in humans with co-infusion of GIP and GIP(3-30)NH2","journal":"Diabetologia","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro receptor specificity panel plus rigorous randomized crossover clamp study in humans confirming functional antagonism","pmids":["28948296"],"is_preprint":false},{"year":2010,"finding":"PPARγ binds to a PPAR response element (PPRE) in the GIP receptor (GIP-R) promoter and regulates GIP-R transcription. Pancreas-specific PPARγ knockout mice show ~70% reduction in islet GIP-R protein. Thiazolidinedione activation of PPARγ in normal mouse islets causes ~3-fold increase in GIP-R protein and doubles insulin secretion in response to glucose+GIP. Hyperglycemia in ZF rats reduces both PPARγ and GIP-R protein, suggesting this pathway mediates GIP resistance in type 2 diabetes.","method":"Chromatin immunoprecipitation, siRNA, luciferase promoter assay in INS-1 cells, pancreas-specific PPARγ knockout mice, islet immunohistochemistry and protein expression","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — ChIP, siRNA, reporter assay, and genetic knockout model all supporting the same mechanistic conclusion","pmids":["20332343"],"is_preprint":false},{"year":2020,"finding":"Tirzepatide (dual GIP/GLP-1 receptor agonist) mimics native GIP at the GIP receptor but shows biased agonism at the GLP-1 receptor, favoring cAMP generation over β-arrestin recruitment, and produces weaker GLP-1 receptor internalization than native GLP-1. β-arrestin1 limits the insulin response to GLP-1 but not to GIP or tirzepatide in primary islets, suggesting that tirzepatide's GLP-1 receptor bias enhances insulin secretion. Receptor occupancy analysis shows greater engagement of tirzepatide at GIPR than GLP-1R at clinical doses.","method":"Receptor occupancy calculation, cAMP signaling assays, β-arrestin recruitment assays, receptor internalization assays, primary islet insulin secretion with β-arrestin1 manipulation","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — multiple in vitro signaling assays plus primary islet functional experiments in one rigorous study","pmids":["32730231"],"is_preprint":false},{"year":2021,"finding":"CNS GIPR signaling is required for the weight-reducing and food-intake-suppressing effects of GIP and GLP-1/GIP co-agonism. CNS-specific Gipr knockout mice and humanized GIPR knockin mice with CNS-hGIPR deletion on HFD show decreased body weight and improved glucose metabolism. Acute central and peripheral administration of acyl-GIP increases cFos neuronal activity in hypothalamic feeding centers, coinciding with decreased body weight and food intake. The superior metabolic effect of GLP-1/GIP co-agonism relative to GLP-1 is extinguished in CNS-Gipr KO mice.","method":"CNS-specific Gipr knockout mice, humanized GIPR knockin mice with CNS deletion, intracerebroventricular and peripheral administration of acyl-GIP, cFos immunohistochemistry, body weight and food intake measurements, epistasis with CNS-Gipr KO","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with CNS-specific KO combined with pharmacological and imaging approaches, replicated across multiple mouse models","pmids":["33571454"],"is_preprint":false},{"year":2021,"finding":"GIPR activation attenuates GLP-1R agonist-induced nausea and emesis while maintaining reduced food intake and body weight. Single-nuclei RNA sequencing of the area postrema/nucleus tractus solitarius (AP/NTS) identifies distinct neuronal populations expressing GIPR (predominantly GABAergic neurons) and GLP-1R (predominantly excitatory neurons). GIPR agonism in these GABAergic neurons blocks emetic and illness behaviors in multiple species.","method":"Behavioral pharmacology (emesis/nausea assays in mice, rats, musk shrews), single-nuclei RNA sequencing of AP/NTS, species comparison across three mammalian species","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 2 / Strong — snRNA-seq cell-type identification combined with pharmacological loss-of-function in three species","pmids":["34380697"],"is_preprint":false},{"year":2018,"finding":"GIP directly stimulates osteopontin (OPN) protein expression in a dose-dependent manner in rat primary adipocytes. A loss-of-function variant of GIPR (rs10423928) that reduces exon 9-containing receptor isoform (required for transmembrane activity) is associated with lower adipose tissue OPN mRNA and better insulin sensitivity in obese individuals.","method":"GIP treatment of primary rat adipocytes with OPN protein measurement, human genetic association of GIPR variant with adipose OPN mRNA and insulin sensitivity measures","journal":"Diabetes","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — direct in vitro stimulation assay plus human genetic data, but in vitro work done in rat adipocytes (not human) and genetic data is associative","pmids":["23349498"],"is_preprint":false},{"year":2019,"finding":"GIP directly reduces osteoclast activity through multiple signaling pathways (Src, cAMP, Akt, p38, NFκB) impairing nuclear translocation of NFATc1 and NFκB, inhibiting osteoclastogenesis, delaying bone resorption, and increasing osteoclast apoptosis in primary human osteoclasts. GIP also improves osteoblast survival. GIPR is robustly expressed in mature human osteoclasts (confirmed by RNA-seq and in situ hybridization). All effects are abolished by the GIPR antagonist GIP(3-30)NH2.","method":"Primary human osteoclast and osteoblast cultures, RNA-seq, in situ hybridization, LANCE cAMP assay, AlphaLISA phosphorylation assays, intracellular calcium imaging, confocal microscopy for NFATc1/NFκB localization, Seahorse bioenergetics, GIPR antagonist blockade","journal":"European journal of endocrinology","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — primary human cells with multiple orthogonal signaling assays plus pharmacological blockade confirming GIPR mediation","pmids":["36747334"],"is_preprint":false},{"year":2019,"finding":"Using GIP(3-30)NH2, GIP receptor antagonism in healthy men reduces GIP-induced suppression of the bone resorption marker CTX by ~51% during hyperglycemic clamp, and attenuates GIP-stimulated P1NP (bone formation marker) and PTH suppression. These effects are GIPR-mediated.","method":"Randomized double-blind placebo-controlled crossover study, hyperglycemic clamp with GIP ± GIP(3-30)NH2 infusion, CTX and P1NP measurements","journal":"Bone","confidence":"High","confidence_rationale":"Tier 2 / Moderate — rigorous randomized crossover clamp study in humans with selective receptor antagonist confirming mechanism","pmids":["31622777"],"is_preprint":false},{"year":2020,"finding":"Endogenous GIP (during a mixed meal) contributes ~22–25% to postprandial suppression of bone resorption (CTX) in healthy humans, as demonstrated by GIPR antagonism with GIP(3-30)NH2. Endogenous GLP-1 had no detectable effect on bone resorption. Combined GIP and GLP-1 receptor antagonism additively impaired postprandial glycemic control and insulin secretion, indicating their effects on glucose homeostasis are additive. Only GIP affected gallbladder motility.","method":"Randomized double-blind placebo-controlled crossover study with four-arm design (GIP antagonist, GLP-1 antagonist, both, placebo) during OGTT and mixed meal test in healthy men","journal":"Bone / The Journal of clinical endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — rigorous randomized crossover human study with selective receptor antagonists, replicated across two meal types","pmids":["32730920","32077470"],"is_preprint":false},{"year":2018,"finding":"Myeloid cell-specific GIPR deficiency in HFD-fed mice leads to greater weight gain, insulin resistance, hepatic steatosis, impaired energy expenditure, reduced WAT beiging, and myelopoiesis. GIP directly downregulates S100A8 expression in adipose tissue macrophages, and co-deletion of GIPR and S100A8/A9 in immune cells ameliorates the metabolic phenotype. This identifies a myeloid-GIPR-S100A8/A9 signaling axis coupling nutrient signals to inflammation and adaptive thermogenesis.","method":"Myeloid-specific Gipr knockout mice, HFD feeding, metabolic phenotyping, gene expression in WAT macrophages, direct GIP treatment of macrophages, genetic epistasis with S100A8/A9 co-deletion","journal":"Nature metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type specific KO, direct macrophage treatment, and genetic epistasis with co-deletion, multiple orthogonal methods","pmids":["32694806"],"is_preprint":false},{"year":2019,"finding":"GIPR is expressed in murine brown adipose tissue (BAT). GIP directly increases Il6 mRNA and IL-6 secretion in BAT cells. BAT-specific (Myf5 domain) Gipr knockout mice exhibit higher body temperature during acute cold challenge, lower respiratory exchange ratio, and impaired lipid tolerance at room temperature. At 4°C, GiprBAT-/- mice show lower body weight and higher iBAT oxygen consumption, indicating the BAT GIPR links to thermogenic fuel utilization and oxygen consumption.","method":"BAT cell culture with GIP treatment, siRNA knockdown of Gipr in BAT cells with gene expression, BAT-specific (GiprBAT-/-) knockout mice, metabolic cage phenotyping, cold challenge, ex vivo iBAT oxygen consumption","journal":"Molecular metabolism","confidence":"High","confidence_rationale":"Tier 2 / Moderate — tissue-specific KO with functional phenotype, direct cell treatment, multiple metabolic readouts","pmids":["31451430"],"is_preprint":false},{"year":2023,"finding":"β-arrestin 2 (ARRB2) mediates distinct roles in GLP-1R versus GIPR signaling in pancreatic β cells. For GIPR, ARRB2 is required for GIP-potentiated insulin secretion in both mouse and human islets. The GIPR-ARRB2 axis does not regulate cAMP/PKA or ERK signaling but mediates GIP-induced F-actin depolymerization. In contrast, for GLP-1R, ARRB2 dampens insulin secretion at physiological doses. The dual agonist tirzepatide does not require ARRB2 for insulin secretion potentiation.","method":"β-arrestin 2 knockout mouse islets, human islets with reduced ARRB2 (diabetogenic conditions), pharmacological assays for cAMP/PKA and ERK, F-actin staining, insulin secretion assays","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — genetic KO and direct signaling assays in both mouse and human islets, multiple orthogonal readouts","pmids":["37897727"],"is_preprint":false},{"year":2021,"finding":"Spatiotemporal analysis shows that GLP-1/GIP dual agonists MAR709 and tirzepatide induce diminished ligand-induced receptor internalization at both GIP and GLP-1 receptors compared to native agonists, while preserving maximal cAMP production despite partial Gαs recruitment. GLP-1R co-localization with Rab11-associated recycling endosomes was not different between MAR709 and GLP-1R mono-agonists.","method":"BRET-based Gαs recruitment and internalization assays, live-cell HILO microscopy for receptor trafficking, comparison across mono- and dual-agonists","journal":"Molecular metabolism","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — BRET and live-cell microscopy provide quantitative receptor dynamics, multiple agonist comparisons","pmids":["33556643"],"is_preprint":false},{"year":2021,"finding":"GIP administered centrally (ICV) increases hypothalamic proinflammatory markers (Il-6, Socs3) and activates IκB kinase-β (IKKβ) inflammatory signaling. GIP also reduces anorectic insulin actions in the brain and diminishes insulin-induced phosphorylation of Akt and GSK3β in the hypothalamus. An antagonistic GIPR antibody and GIPR deficiency both significantly reduce proinflammatory cytokines and Socs3 in the hypothalamus during HFD feeding.","method":"ICV GIP administration in mice, unbiased RNA sequencing of GIP-stimulated hypothalami, GIPR antibody treatment, GIPR knockout mice, phospho-Akt and phospho-GSK3β Western blot, cytokine measurement","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple in vivo approaches with genetic and pharmacological loss-of-function, single lab","pmids":["32603429"],"is_preprint":false},{"year":2024,"finding":"GIPR induction exclusively in adipocytes activates SERCA-mediated futile calcium cycling in white adipose tissue, increasing lipid oxidation, thermogenesis, and energy expenditure. Adipocyte-specific GIPR induction protects mice from diet-induced obesity and causes ~35% weight loss in obese mice. A 'metabolic memory' effect maintains weight loss after the transgene is switched off.","method":"Inducible adipocyte-specific GIPR transgenic mouse model, calcium flux assays, thermogenesis and energy expenditure measurement, body composition analysis, SERCA pathway interrogation","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 / Moderate — adipocyte-specific gain-of-function model with mechanistic identification of SERCA-mediated futile calcium cycling","pmids":["39642881"],"is_preprint":false},{"year":2024,"finding":"Long-acting GIPR agonism in human adipocytes and diet-induced obese mice: in the fed (insulin-present) state, GIPR agonism enhances insulin signaling, augments glucose uptake, and increases glucose-to-glycerol conversion cooperatively with insulin. In the fasted (insulin-absent) state, GIPR agonism increases lipolysis. In vivo, a long-acting GIPR agonist reduces circulating triglycerides during oral lipid challenge and increases lipoprotein-derived fatty acid uptake into adipose tissue.","method":"Human adipocyte functional assays (glucose uptake, glycerol production, lipolysis), DIO mouse model with long-acting GIPR agonist treatment, oral lipid challenge with triglyceride and fatty acid tracer measurement","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 / Moderate — human adipocyte assays plus in vivo DIO mouse model, multiple functional readouts across fed/fasted states","pmids":["38878772"],"is_preprint":false},{"year":2021,"finding":"GIP receptor agonism blocks emesis and attenuates illness behaviors (nausea surrogates) elicited by GLP-1R activation in mice, rats, and musk shrews, while maintaining GLP-1R agonist-induced reduction in food intake, body weight, and improved glucose tolerance. The area postrema/NTS of the hindbrain mediates these effects, and GIPR is most highly expressed in GABAergic neurons in this region.","method":"Multi-species pharmacological experiments (mice, rats, musk shrews), snRNA-seq of AP/NTS, GIPR agonist co-administration with GLP-1R agonists, food intake and emesis behavioral assays","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 2 / Strong — cross-species replication, snRNA-seq cell-type identification, pharmacological dissection of specific behaviors","pmids":["34380697"],"is_preprint":false},{"year":2021,"finding":"Structural and mutational analysis of the GIP receptor using a homology model of GIPR based on GLP-1R, combined with molecular dynamics and in vitro mutagenesis, identifies R183(2.60), R190(2.67), and R300(5.40) as key residues for GIPR activation. Disruption of a K293(ECL2)–E362(ECL3) salt bridge by GIPR antagonists strongly reduces GIPR activation. GIP(1-30)NH2 and GIP(1-42) have different binding modes compared with antagonists GIP(3-30)NH2 and GIP(5-30)NH2.","method":"Homology modeling, molecular dynamics simulation, in vitro site-directed mutagenesis with cAMP and binding assays","journal":"Structure","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — computational modeling validated by in vitro mutagenesis, single lab; homology model (not crystal structure) reduces tier","pmids":["33891864"],"is_preprint":false},{"year":2017,"finding":"Ectopic GIPR expression in adrenocortical adenomas causing GIP-dependent Cushing's syndrome occurs through monoallelic transcriptional activation of the GIPR gene. In some adrenal lesions, this is driven by somatic chromosomal duplications in the 19q13.32 region containing the GIPR locus, with rearrangements juxtaposing cis-acting regulatory sequences (including glucocorticoid response elements) to the translocated GIPR allele, driving its aberrant expression.","method":"Array-comparative genomic hybridization, RNA/DNA FISH, RRBS DNA methylation analysis, molecular analysis of adrenocortical lesions from 14 patients","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — molecular genomic analyses in patient tissue, multiple methods, but single center","pmids":["28931750"],"is_preprint":false},{"year":2009,"finding":"GIP is rapidly inactivated primarily by N-terminal cleavage by dipeptidyl peptidase IV (DPP IV/CD26) on the cell surface of endothelial and epithelial cells, generating inactive metabolites. Cleavage by neprilysin (neutral endopeptidase) is a minor degradation route. Renal clearance eliminates incretin fragments but is of less importance for regulating incretin bioactivity.","method":"Biochemical degradation studies establishing DPP-IV as the primary inactivating enzyme (review synthesizing multiple mechanism studies)","journal":"Best practice & research. Clinical endocrinology & metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Strong — enzymatic mechanism well established across multiple prior studies; this paper synthesizes evidence rather than providing primary data","pmids":["19748062"],"is_preprint":false},{"year":2024,"finding":"Stimulating intestinal GIP release via chemogenetic activation (hM3Dq DREADD) of GIP-expressing K-cells in mice increases plasma GIP to postprandial levels and produces a robust inhibition of food intake. This anorectic effect is prevented by peripheral or central injection of antagonistic GIPR antibodies and reproduced when Dq expression is restricted to intestinal K-cells. The effect is maintained in diet-induced obese mice, with chronic K-cell activation reducing food intake and attenuating body weight gain.","method":"GIP-Dq DREADD mouse model, chemogenetic K-cell activation, peripheral and central GIPR antibody injection, intersectional Gip-Cre/Villin-Flp model, plasma GIP measurement, food intake and body weight assays","journal":"Molecular metabolism","confidence":"High","confidence_rationale":"Tier 2 / Moderate — chemogenetic gain-of-function plus pharmacological blockade plus intersectional genetic model, multiple replications in same study","pmids":["38653401"],"is_preprint":false},{"year":2015,"finding":"GLP-1-producing L-cells and GIP-producing K-cells rarely overlap (~5% co-expression) and differ by bombesin receptor-2 expression. Bombesin/neuromedin C stimulates GLP-1 but not GIP secretion, consistent with selective expression of the bombesin receptor-2 in L-cells but not K-cells, as demonstrated in isolated perfused mouse intestine and primary cultured intestinal cells.","method":"Transgenic mice with fluorescent markers in GIP-positive and GLP-1-positive cells, secretion assays in isolated perfused mouse intestine and primary cultured intestinal cells, expression analysis of bombesin receptor-2","journal":"The Journal of endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — transgenic dual-reporter model plus functional secretion assays in native intestinal preparations","pmids":["26483393"],"is_preprint":false},{"year":2024,"finding":"GLP-1R/GIPR agonists (liraglutide, acyl-GIP, and MAR709) have no direct actions in human hepatocytes or hepatic stellate cells at concentrations effective for insulin release. None reduced lipid content in oleic/palmitic acid-loaded hepatocytes, nor improved fibrotic marker expression in TGFβ-activated HSCs, nor induced CREB phosphorylation in either cell type.","method":"Human hepatocyte and HSC cell lines and primary cells treated with GLP-1R/GIPR agonists; lipid content assay, fibrotic marker expression, CREB phosphorylation assay","journal":"Cellular and molecular life sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct cell treatment with multiple readouts in both cell lines and primary cells; finding is a negative result (no direct hepatocyte/HSC action)","pmids":["39607493"],"is_preprint":false}],"current_model":"GIP (glucose-dependent insulinotropic polypeptide) is a 42-amino acid incretin hormone secreted by intestinal K-cells that acts through a seven-transmembrane Gαs-coupled receptor (GIPR), activating adenylate cyclase to raise intracellular cAMP and, in β-cells, stimulating glucose-dependent insulin secretion via PKA and β-arrestin 2-dependent pathways; N-glycosylation of the GIPR extracellular domain is required for its plasma-membrane expression and function; GIP is rapidly inactivated by DPP-IV cleavage; beyond the pancreas, GIP regulates adipocyte lipid metabolism (upregulating LPL transcription via PI3-K/PKB/AMPK-CREB/TORC2 and promoting fed-state glucose/lipid uptake while enhancing lipolysis when insulin is absent) through direct GIPR signaling, activates SERCA-mediated futile calcium cycling in adipocytes to increase energy expenditure, suppresses bone resorption by inhibiting osteoclastogenesis via Src/cAMP/Akt/NFκB/NFATc1 pathways in primary human osteoclasts, modulates hypothalamic inflammation and insulin resistance through CNS GIPR signaling, attenuates GLP-1-induced nausea/emesis via hindbrain GABAergic neurons, and downregulates S100A8/A9 in myeloid cells to restrain adipose inflammation."},"narrative":{"mechanistic_narrative":"GIP (glucose-dependent insulinotropic polypeptide) is an intestinal incretin hormone whose release from K-cells couples nutrient sensing to systemic metabolic, skeletal, and central control through its dedicated seven-transmembrane Gαs-coupled receptor GIPR, which raises intracellular cAMP upon ligand binding and discriminates GIP from related secretin-family peptides [PMID:7589426]. Within pancreatic β-cells GIPR potentiates glucose-induced insulin secretion, a response requiring N-glycosylation of the receptor's extracellular domain for plasma-membrane expression and receptor stability [PMID:22412906], and dependent on β-arrestin 2, which mediates GIP-induced F-actin depolymerization without engaging cAMP/PKA or ERK [PMID:37897727]; GIPR transcription is itself controlled by PPARγ acting at a promoter PPRE, linking adipokine signaling to incretin sensitivity [PMID:20332343]. Beyond the pancreas, GIP acts directly on adipocytes to drive insulin-cooperative glucose uptake and fed-state lipid storage while promoting fasting-state lipolysis [PMID:38878772] and, through adipocyte GIPR, activates SERCA-mediated futile calcium cycling that increases thermogenesis and energy expenditure [PMID:39642881]; in primary human osteoclasts it suppresses osteoclastogenesis and bone resorption via Src/cAMP/Akt/NFκB/NFATc1 signaling [PMID:36747334], a function confirmed in humans where GIPR antagonism reverses GIP-driven suppression of bone resorption [PMID:31622777, PMID:32730920, PMID:32077470]. Central GIPR signaling is required for the weight-reducing and anorectic effects of GIP and GLP-1/GIP co-agonism [PMID:33571454], and GIPR-expressing GABAergic neurons in the area postrema/NTS mediate suppression of GLP-1R-agonist-induced nausea and emesis [PMID:34380697]. GIP is rapidly inactivated by N-terminal cleavage by DPP-IV [PMID:19748062], and selective antagonism with GIP(3-30)NH2 establishes the receptor's causal role in insulin secretion and bone resorption in humans [PMID:28948296]. Pharmacologically, dual GIP/GLP-1 agonists such as tirzepatide mimic native GIP at GIPR while showing biased, internalization-sparing agonism at GLP-1R [PMID:32730231, PMID:33556643].","teleology":[{"year":1995,"claim":"Establishing the molecular identity and signaling output of the GIP receptor answered how GIP transduces its hormonal signal, defining it as a Gαs-coupled GPCR specific for GIP.","evidence":"Molecular cloning from human insulinoma cDNA, stable expression in CHL fibroblasts, radioligand binding and cAMP assays with a secretin-family specificity panel","pmids":["7589426"],"confidence":"High","gaps":["No structural model of ligand engagement at this stage","Calcium signaling absent in fibroblasts but not tested in native cell types"]},{"year":2007,"claim":"Discovery of a dominant-negative truncated GIPR splice variant explained how receptor surface availability is tuned and linked isoform balance to GIP sensitivity in obesity.","evidence":"Co-expression of truncated and wild-type GIPR with cAMP and surface-expression assays, RT-PCR and islet secretion in diet-induced obese mice","pmids":["17971513"],"confidence":"High","gaps":["Mechanism of reduced surface expression of wild-type receptor not resolved","Human relevance of the splice variant ratio not established"]},{"year":2010,"claim":"Defining PPARγ control of GIPR transcription and the GIP-driven LPL induction pathway connected receptor expression and adipocyte lipid handling to nuclear regulatory programs.","evidence":"ChIP, siRNA, luciferase reporters in INS-1 cells, pancreas-specific PPARγ KO mice; and LPL promoter reporter, ChIP, siRNA and co-IP in GIPR-expressing cells","pmids":["20332343","20693566"],"confidence":"High","gaps":["Whether insulin-context switching between cAMP/PKA and PI3-K/PKB pathways occurs in vivo unresolved","Direct demonstration of PPARγ-GIPR axis driving human GIP resistance not shown"]},{"year":2012,"claim":"Identifying N-glycosylation of the GIPR extracellular domain answered why receptor surface expression and insulinotropic function depend on post-translational processing, and uncovered GIP-GLP-1 receptor heteromerization.","evidence":"Site-directed mutagenesis of Asn sites, surface expression and half-life assays, INS-1 insulin secretion, and BRET","pmids":["22412906"],"confidence":"High","gaps":["Functional consequence of the GIP-GLP-1 heteromer in native cells unknown","Whether glycosylation is dynamically regulated not addressed"]},{"year":2017,"claim":"Development of the selective antagonist GIP(3-30)NH2 enabled causal interrogation of GIPR in humans, proving GIP's dominant contribution to glucose-stimulated insulin secretion; and ectopic GIPR genomics explained GIP-dependent Cushing's syndrome.","evidence":"Receptor specificity panel in COS-7 cells plus randomized crossover hyperglycemic clamp in healthy men; and aCGH, FISH and methylation analysis of adrenocortical lesions","pmids":["28948296","28931750"],"confidence":"High","gaps":["Single-center genomic analysis of adrenal lesions","Antagonist effects on non-pancreatic tissues not yet mapped at this stage"]},{"year":2019,"claim":"Establishing direct GIP action in primary human osteoclasts and confirming it with human antagonist studies answered how GIP couples nutrient intake to skeletal homeostasis.","evidence":"Primary human osteoclast/osteoblast cultures, RNA-seq, signaling and bioenergetics assays with GIPR antagonist; and randomized crossover clamp with GIP ± GIP(3-30)NH2 measuring CTX/P1NP","pmids":["36747334","31622777"],"confidence":"High","gaps":["Long-term skeletal consequences of GIP signaling not established","Relative contribution of each signaling arm (Src/cAMP/Akt/NFκB) not quantified"]},{"year":2019,"claim":"Tissue-specific GIPR deletion in brown adipose tissue and myeloid cells revealed peripheral GIPR roles in thermogenic fuel use and adipose inflammation beyond the pancreas.","evidence":"BAT-specific and myeloid-specific Gipr knockout mice with metabolic phenotyping, direct cell treatment, and genetic epistasis with S100A8/A9 co-deletion","pmids":["31451430","32694806"],"confidence":"High","gaps":["Whether the myeloid-GIPR-S100A8/A9 axis operates in humans unknown","Reconciliation of GIPR agonism versus deficiency both yielding metabolic benefit unresolved"]},{"year":2020,"claim":"Quantifying the endogenous incretin contribution to postprandial physiology and characterizing tirzepatide's biased agonism clarified GIP's physiological footprint and the pharmacology of dual agonists.","evidence":"Four-arm randomized antagonist crossover study in healthy men; and receptor occupancy, cAMP, β-arrestin and internalization assays with primary islet secretion","pmids":["32730920","32077470","32730231"],"confidence":"High","gaps":["Mechanism of additive glucose effects of GIP and GLP-1 not molecularly dissected","Tissue selectivity of tirzepatide engagement at clinical doses incompletely mapped"]},{"year":2021,"claim":"Defining CNS and hindbrain GIPR functions answered how central GIPR signaling mediates weight loss, food-intake suppression, hypothalamic inflammation, and protection from GLP-1-induced nausea.","evidence":"CNS-specific and humanized Gipr knockout mice with cFos imaging; snRNA-seq of AP/NTS with multi-species behavioral pharmacology; ICV GIP with RNA-seq, antibody and KO loss-of-function; and structural homology modeling with mutagenesis","pmids":["33571454","34380697","32603429","33891864"],"confidence":"High","gaps":["Crystal/cryo-EM structure of GIPR-ligand complex not available (homology model only)","Mechanism linking GABAergic GIPR neurons to anti-emetic output not resolved","CNS hypothalamic inflammation findings are single-lab and Medium confidence"]},{"year":2023,"claim":"Dissecting β-arrestin 2 dependence distinguished GIPR from GLP-1R signaling logic, showing ARRB2 is required for GIP-potentiated insulin secretion via F-actin remodeling rather than cAMP.","evidence":"β-arrestin 2 knockout mouse islets and ARRB2-reduced human islets with cAMP/PKA, ERK, F-actin and insulin secretion assays","pmids":["37897727"],"confidence":"High","gaps":["Molecular link between ARRB2 and F-actin depolymerization not defined","Relevance to non-islet GIPR-expressing tissues untested"]},{"year":2024,"claim":"Adipocyte and K-cell gain-of-function models, fed/fasted adipocyte pharmacology, and a hepatocyte negative-control study refined where GIPR agonism acts to drive weight loss and energy expenditure.","evidence":"Inducible adipocyte-specific GIPR transgenic mice with SERCA calcium cycling analysis; chemogenetic K-cell activation with GIPR antibody blockade; human adipocyte fed/fasted functional assays plus DIO mouse lipid challenge; and direct GLP-1R/GIPR agonist treatment of human hepatocytes/HSCs","pmids":["39642881","38653401","38878772","39607493"],"confidence":"High","gaps":["Mechanism of the 'metabolic memory' weight-loss persistence unknown","Whether intestinal K-cell-driven anorexia operates in humans untested","Hepatic absence of effect is a negative result requiring dose/context boundaries"]},{"year":null,"claim":"How GIPR agonism and GIPR loss-of-function can both yield metabolic benefit, and the high-resolution structural basis of agonist versus antagonist binding, remain unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No experimental atomic structure of the GIPR-ligand complex","Reconciliation of agonist-vs-antagonist metabolic benefit paradox unresolved","Human translation of CNS and adipocyte mouse mechanisms incomplete"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,4,6]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[3,0]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[23,24]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,6,15]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[18,19,14]}],"complexes":[],"partners":["GIPR","DPP4","GLP1R","ARRB2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P09681","full_name":"Gastric inhibitory polypeptide","aliases":["Glucose-dependent insulinotropic polypeptide","Incretin hormone"],"length_aa":153,"mass_kda":17.1,"function":"Potent stimulator of insulin secretion and relatively poor inhibitor of gastric acid secretion","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P09681/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GIP","classification":"Not Classified","n_dependent_lines":9,"n_total_lines":1208,"dependency_fraction":0.0074503311258278145},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/GIP","total_profiled":1310},"omim":[{"mim_id":"620990","title":"ACTH-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA 3; AIMAH3","url":"https://www.omim.org/entry/620990"},{"mim_id":"619128","title":"HYDROXYPYRUVATE ISOMERASE; HYI","url":"https://www.omim.org/entry/619128"},{"mim_id":"612659","title":"REGULATORY FACTOR X, 6; RFX6","url":"https://www.omim.org/entry/612659"},{"mim_id":"610365","title":"C1q- AND TUMOR NECROSIS FACTOR-RELATED PROTEIN 1; C1QTNF1","url":"https://www.omim.org/entry/610365"},{"mim_id":"609132","title":"LYSINE DEMETHYLASE 1A; KDM1A","url":"https://www.omim.org/entry/609132"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"intestine","ntpm":243.9}],"url":"https://www.proteinatlas.org/search/GIP"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P09681","domains":[{"cath_id":"-","chopping":"62-108","consensus_level":"medium","plddt":79.597,"start":62,"end":108}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P09681","model_url":"https://alphafold.ebi.ac.uk/files/AF-P09681-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P09681-F1-predicted_aligned_error_v6.png","plddt_mean":69.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GIP","jax_strain_url":"https://www.jax.org/strain/search?query=GIP"},"sequence":{"accession":"P09681","fasta_url":"https://rest.uniprot.org/uniprotkb/P09681.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P09681/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P09681"}},"corpus_meta":[{"pmid":"17498508","id":"PMC_17498508","title":"Biology of incretins: GLP-1 and GIP.","date":"2007","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/17498508","citation_count":2816,"is_preprint":false},{"pmid":"24843404","id":"PMC_24843404","title":"GIP and GLP-1, the two incretin hormones: Similarities and differences.","date":"2010","source":"Journal of diabetes investigation","url":"https://pubmed.ncbi.nlm.nih.gov/24843404","citation_count":562,"is_preprint":false},{"pmid":"32730231","id":"PMC_32730231","title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.","date":"2020","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/32730231","citation_count":381,"is_preprint":false},{"pmid":"32396843","id":"PMC_32396843","title":"How May GIP Enhance the Therapeutic Efficacy of GLP-1?","date":"2020","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/32396843","citation_count":338,"is_preprint":false},{"pmid":"34310013","id":"PMC_34310013","title":"The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.","date":"2021","source":"Diabetes, obesity & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/34310013","citation_count":294,"is_preprint":false},{"pmid":"33236115","id":"PMC_33236115","title":"Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes.","date":"2021","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/33236115","citation_count":257,"is_preprint":false},{"pmid":"33571454","id":"PMC_33571454","title":"The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling.","date":"2021","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/33571454","citation_count":256,"is_preprint":false},{"pmid":"10666005","id":"PMC_10666005","title":"GIP biology and fat metabolism.","date":"2000","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/10666005","citation_count":228,"is_preprint":false},{"pmid":"35985340","id":"PMC_35985340","title":"LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.","date":"2022","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/35985340","citation_count":226,"is_preprint":false},{"pmid":"15464590","id":"PMC_15464590","title":"GPCR interacting proteins (GIP).","date":"2004","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/15464590","citation_count":203,"is_preprint":false},{"pmid":"31029770","id":"PMC_31029770","title":"The incretin system in healthy humans: The role of GIP and GLP-1.","date":"2019","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/31029770","citation_count":177,"is_preprint":false},{"pmid":"36509857","id":"PMC_36509857","title":"Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1.","date":"2022","source":"Nature reviews. Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/36509857","citation_count":175,"is_preprint":false},{"pmid":"34380697","id":"PMC_34380697","title":"GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist-Induced Nausea and Emesis in Preclinical Models.","date":"2021","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/34380697","citation_count":164,"is_preprint":false},{"pmid":"15655703","id":"PMC_15655703","title":"On the physiology of GIP and GLP-1.","date":"2004","source":"Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","url":"https://pubmed.ncbi.nlm.nih.gov/15655703","citation_count":153,"is_preprint":false},{"pmid":"32459834","id":"PMC_32459834","title":"GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists.","date":"2020","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/32459834","citation_count":150,"is_preprint":false},{"pmid":"21820006","id":"PMC_21820006","title":"Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and β cell preservation.","date":"2011","source":"Progress in biophysics and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/21820006","citation_count":150,"is_preprint":false},{"pmid":"34932984","id":"PMC_34932984","title":"Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist.","date":"2021","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/34932984","citation_count":145,"is_preprint":false},{"pmid":"12529935","id":"PMC_12529935","title":"Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors.","date":"2002","source":"Receptors & channels","url":"https://pubmed.ncbi.nlm.nih.gov/12529935","citation_count":140,"is_preprint":false},{"pmid":"19251046","id":"PMC_19251046","title":"Glucose-dependent insulinotropic polypeptide (Gastric Inhibitory Polypeptide; GIP).","date":"2009","source":"Vitamins and hormones","url":"https://pubmed.ncbi.nlm.nih.gov/19251046","citation_count":132,"is_preprint":false},{"pmid":"15780432","id":"PMC_15780432","title":"GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.","date":"2005","source":"Regulatory peptides","url":"https://pubmed.ncbi.nlm.nih.gov/15780432","citation_count":131,"is_preprint":false},{"pmid":"18640588","id":"PMC_18640588","title":"Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes.","date":"2008","source":"Diabetes & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/18640588","citation_count":130,"is_preprint":false},{"pmid":"16142014","id":"PMC_16142014","title":"Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes.","date":"2005","source":"Diabetes & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/16142014","citation_count":119,"is_preprint":false},{"pmid":"35065096","id":"PMC_35065096","title":"GLP-1 and GIP receptor signaling in beta cells - A review of receptor interactions and co-stimulation.","date":"2022","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/35065096","citation_count":116,"is_preprint":false},{"pmid":"35809773","id":"PMC_35809773","title":"Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice.","date":"2022","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/35809773","citation_count":114,"is_preprint":false},{"pmid":"20693566","id":"PMC_20693566","title":"GIP increases human adipocyte LPL expression through CREB and TORC2-mediated trans-activation of the LPL gene.","date":"2010","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/20693566","citation_count":110,"is_preprint":false},{"pmid":"28610922","id":"PMC_28610922","title":"Central administration of GLP-1 and GIP decreases feeding in mice.","date":"2017","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/28610922","citation_count":97,"is_preprint":false},{"pmid":"34608929","id":"PMC_34608929","title":"Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes.","date":"2022","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/34608929","citation_count":94,"is_preprint":false},{"pmid":"31693916","id":"PMC_31693916","title":"Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists.","date":"2019","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/31693916","citation_count":91,"is_preprint":false},{"pmid":"19748067","id":"PMC_19748067","title":"Therapeutic potential for GIP receptor agonists and antagonists.","date":"2009","source":"Best practice & research. Clinical endocrinology & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/19748067","citation_count":90,"is_preprint":false},{"pmid":"31705913","id":"PMC_31705913","title":"GIP has neuroprotective effects in Alzheimer and Parkinson's disease models.","date":"2019","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/31705913","citation_count":84,"is_preprint":false},{"pmid":"38878772","id":"PMC_38878772","title":"Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor.","date":"2024","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/38878772","citation_count":82,"is_preprint":false},{"pmid":"33556643","id":"PMC_33556643","title":"Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists.","date":"2021","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/33556643","citation_count":80,"is_preprint":false},{"pmid":"31785304","id":"PMC_31785304","title":"The role of GIP in α-cells and glucagon secretion.","date":"2019","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/31785304","citation_count":80,"is_preprint":false},{"pmid":"14607102","id":"PMC_14607102","title":"Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential?","date":"2003","source":"Neuropeptides","url":"https://pubmed.ncbi.nlm.nih.gov/14607102","citation_count":79,"is_preprint":false},{"pmid":"28948296","id":"PMC_28948296","title":"GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study.","date":"2017","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/28948296","citation_count":79,"is_preprint":false},{"pmid":"21864749","id":"PMC_21864749","title":"Incretin effect: GLP-1, GIP, DPP4.","date":"2011","source":"Diabetes research and clinical practice","url":"https://pubmed.ncbi.nlm.nih.gov/21864749","citation_count":78,"is_preprint":false},{"pmid":"23349498","id":"PMC_23349498","title":"Link between GIP and osteopontin in adipose tissue and insulin resistance.","date":"2013","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/23349498","citation_count":78,"is_preprint":false},{"pmid":"7589426","id":"PMC_7589426","title":"Molecular cloning, functional expression, and signal transduction of the GIP-receptor cloned from a human insulinoma.","date":"1995","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/7589426","citation_count":78,"is_preprint":false},{"pmid":"34819089","id":"PMC_34819089","title":"The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.","date":"2021","source":"Cardiovascular diabetology","url":"https://pubmed.ncbi.nlm.nih.gov/34819089","citation_count":77,"is_preprint":false},{"pmid":"17971513","id":"PMC_17971513","title":"A novel GIP receptor splice variant influences GIP sensitivity of pancreatic beta-cells in obese mice.","date":"2007","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/17971513","citation_count":67,"is_preprint":false},{"pmid":"29412817","id":"PMC_29412817","title":"Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents.","date":"2018","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/29412817","citation_count":65,"is_preprint":false},{"pmid":"19748062","id":"PMC_19748062","title":"Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP.","date":"2009","source":"Best practice & research. Clinical endocrinology & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/19748062","citation_count":64,"is_preprint":false},{"pmid":"31451430","id":"PMC_31451430","title":"Physiological roles of the GIP receptor in murine brown adipose tissue.","date":"2019","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/31451430","citation_count":61,"is_preprint":false},{"pmid":"32694806","id":"PMC_32694806","title":"GIP regulates inflammation and body weight by restraining myeloid-cell-derived S100A8/A9.","date":"2018","source":"Nature metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/32694806","citation_count":60,"is_preprint":false},{"pmid":"3018707","id":"PMC_3018707","title":"The receptors of the VIP family peptides (VIP, secretin, GRF, PHI, PHM, GIP, glucagon and oxyntomodulin). Specificities and identity.","date":"1986","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/3018707","citation_count":60,"is_preprint":false},{"pmid":"17395281","id":"PMC_17395281","title":"GIP receptor mRNA expression in different fat tissue depots in postmenopausal non-diabetic women.","date":"2007","source":"Regulatory peptides","url":"https://pubmed.ncbi.nlm.nih.gov/17395281","citation_count":58,"is_preprint":false},{"pmid":"31443356","id":"PMC_31443356","title":"The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion-A Review.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31443356","citation_count":57,"is_preprint":false},{"pmid":"32077470","id":"PMC_32077470","title":"GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals.","date":"2020","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/32077470","citation_count":56,"is_preprint":false},{"pmid":"34176783","id":"PMC_34176783","title":"The Role of GIP in the Regulation of GLP-1 Satiety and Nausea.","date":"2021","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/34176783","citation_count":54,"is_preprint":false},{"pmid":"37897727","id":"PMC_37897727","title":"GLP-1 and GIP receptors signal through distinct β-arrestin 2-dependent pathways to regulate pancreatic β cell function.","date":"2023","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/37897727","citation_count":53,"is_preprint":false},{"pmid":"34176784","id":"PMC_34176784","title":"The Role of GIP Receptor in the CNS for the Pathogenesis of Obesity.","date":"2021","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/34176784","citation_count":53,"is_preprint":false},{"pmid":"22412906","id":"PMC_22412906","title":"Regulation of GIP and GLP1 receptor cell surface expression by N-glycosylation and receptor heteromerization.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22412906","citation_count":53,"is_preprint":false},{"pmid":"19748060","id":"PMC_19748060","title":"Immunoassays for the incretin hormones GIP and GLP-1.","date":"2009","source":"Best practice & research. Clinical endocrinology & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/19748060","citation_count":52,"is_preprint":false},{"pmid":"29602522","id":"PMC_29602522","title":"High Glycemic Index Metabolic Damage - a Pivotal Role of GIP and GLP-1.","date":"2018","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/29602522","citation_count":51,"is_preprint":false},{"pmid":"31689454","id":"PMC_31689454","title":"Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease.","date":"2019","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/31689454","citation_count":48,"is_preprint":false},{"pmid":"36639119","id":"PMC_36639119","title":"Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes.","date":"2023","source":"Annales d'endocrinologie","url":"https://pubmed.ncbi.nlm.nih.gov/36639119","citation_count":48,"is_preprint":false},{"pmid":"32730920","id":"PMC_32730920","title":"The role of endogenous GIP and GLP-1 in postprandial bone homeostasis.","date":"2020","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/32730920","citation_count":47,"is_preprint":false},{"pmid":"32360365","id":"PMC_32360365","title":"Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors.","date":"2020","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32360365","citation_count":46,"is_preprint":false},{"pmid":"12628351","id":"PMC_12628351","title":"GIP or not GIP? That is the question.","date":"2003","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/12628351","citation_count":45,"is_preprint":false},{"pmid":"32098413","id":"PMC_32098413","title":"GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease-A Systematic Review.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32098413","citation_count":45,"is_preprint":false},{"pmid":"16451070","id":"PMC_16451070","title":"GIP(Lys16PAL) and GIP(Lys37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential.","date":"2006","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16451070","citation_count":44,"is_preprint":false},{"pmid":"20332343","id":"PMC_20332343","title":"Physiologic and pharmacologic modulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta-cells by peroxisome proliferator-activated receptor (PPAR)-gamma signaling: possible mechanism for the GIP resistance in type 2 diabetes.","date":"2010","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/20332343","citation_count":43,"is_preprint":false},{"pmid":"36747334","id":"PMC_36747334","title":"GIP reduces osteoclast activity and improves osteoblast survival in primary human bone cells.","date":"2023","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/36747334","citation_count":43,"is_preprint":false},{"pmid":"26483393","id":"PMC_26483393","title":"GLP1- and GIP-producing cells rarely overlap and differ by bombesin receptor-2 expression and responsiveness.","date":"2015","source":"The Journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/26483393","citation_count":43,"is_preprint":false},{"pmid":"28931750","id":"PMC_28931750","title":"Adrenal GIPR expression and chromosome 19q13 microduplications in GIP-dependent Cushing's syndrome.","date":"2017","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/28931750","citation_count":42,"is_preprint":false},{"pmid":"15655707","id":"PMC_15655707","title":"Physiology of GIP--a lesson from GIP receptor knockout mice.","date":"2004","source":"Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","url":"https://pubmed.ncbi.nlm.nih.gov/15655707","citation_count":40,"is_preprint":false},{"pmid":"39642881","id":"PMC_39642881","title":"The GIP receptor activates futile calcium cycling in white adipose tissue to increase energy expenditure and drive weight loss in mice.","date":"2024","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/39642881","citation_count":39,"is_preprint":false},{"pmid":"31756366","id":"PMC_31756366","title":"GIP analogues and the treatment of obesity-diabetes.","date":"2019","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/31756366","citation_count":38,"is_preprint":false},{"pmid":"35584372","id":"PMC_35584372","title":"Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson's disease.","date":"2022","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/35584372","citation_count":38,"is_preprint":false},{"pmid":"33886495","id":"PMC_33886495","title":"Effects of endogenous GIP in patients with type 2 diabetes.","date":"2021","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/33886495","citation_count":38,"is_preprint":false},{"pmid":"34995796","id":"PMC_34995796","title":"GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment.","date":"2022","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/34995796","citation_count":37,"is_preprint":false},{"pmid":"31715213","id":"PMC_31715213","title":"GIP and the gut-bone axis - Physiological, pathophysiological and potential therapeutic implications.","date":"2019","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/31715213","citation_count":35,"is_preprint":false},{"pmid":"30376114","id":"PMC_30376114","title":"Hypermethylator Phenotype and Ectopic GIP Receptor in GNAS Mutation-Negative Somatotropinomas.","date":"2019","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/30376114","citation_count":34,"is_preprint":false},{"pmid":"36927378","id":"PMC_36927378","title":"GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy.","date":"2023","source":"Expert opinion on pharmacotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/36927378","citation_count":34,"is_preprint":false},{"pmid":"29093273","id":"PMC_29093273","title":"Genetic determinants of circulating GIP and GLP-1 concentrations.","date":"2017","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/29093273","citation_count":33,"is_preprint":false},{"pmid":"31809770","id":"PMC_31809770","title":"Molecular interactions of full-length and truncated GIP peptides with the GIP receptor - A comprehensive review.","date":"2019","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/31809770","citation_count":33,"is_preprint":false},{"pmid":"32603429","id":"PMC_32603429","title":"Gut Hormone GIP Induces Inflammation and Insulin Resistance in the Hypothalamus.","date":"2020","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/32603429","citation_count":33,"is_preprint":false},{"pmid":"31622777","id":"PMC_31622777","title":"GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH2.","date":"2019","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/31622777","citation_count":33,"is_preprint":false},{"pmid":"31838219","id":"PMC_31838219","title":"Recent advances of GIP and future horizons.","date":"2019","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/31838219","citation_count":30,"is_preprint":false},{"pmid":"21995902","id":"PMC_21995902","title":"GIP-dependent expression of hypothalamic genes.","date":"2011","source":"Physiological research","url":"https://pubmed.ncbi.nlm.nih.gov/21995902","citation_count":30,"is_preprint":false},{"pmid":"15655720","id":"PMC_15655720","title":"GIP as a potential therapeutic agent?","date":"2004","source":"Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","url":"https://pubmed.ncbi.nlm.nih.gov/15655720","citation_count":29,"is_preprint":false},{"pmid":"16402925","id":"PMC_16402925","title":"Expression of ACTH receptor pathway genes in glucose-dependent insulinotrophic peptide (GIP)-dependent Cushing's syndrome.","date":"2006","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/16402925","citation_count":28,"is_preprint":false},{"pmid":"34176785","id":"PMC_34176785","title":"Single-Cell Mapping of GLP-1 and GIP Receptor Expression in the Dorsal Vagal Complex.","date":"2021","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/34176785","citation_count":27,"is_preprint":false},{"pmid":"39857719","id":"PMC_39857719","title":"Integrated Management of Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Expanding Roles of SGLT2is, GLP-1RAs, and GIP/GLP-1RAs.","date":"2025","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/39857719","citation_count":26,"is_preprint":false},{"pmid":"37245848","id":"PMC_37245848","title":"GIP receptor agonism blocks chemotherapy-induced nausea and vomiting.","date":"2023","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/37245848","citation_count":26,"is_preprint":false},{"pmid":"31765668","id":"PMC_31765668","title":"GIP analogues augment bone strength by modulating bone composition in diet-induced obesity in mice.","date":"2019","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/31765668","citation_count":26,"is_preprint":false},{"pmid":"35674880","id":"PMC_35674880","title":"Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide.","date":"2022","source":"Clinical pharmacokinetics","url":"https://pubmed.ncbi.nlm.nih.gov/35674880","citation_count":25,"is_preprint":false},{"pmid":"31706956","id":"PMC_31706956","title":"Metabolism of GIP and the contribution of GIP to the glucose-lowering properties of DPP-4 inhibitors.","date":"2019","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/31706956","citation_count":24,"is_preprint":false},{"pmid":"38477667","id":"PMC_38477667","title":"The antiemetic actions of GIP receptor agonism.","date":"2024","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/38477667","citation_count":24,"is_preprint":false},{"pmid":"38653401","id":"PMC_38653401","title":"Stimulating intestinal GIP release reduces food intake and body weight in mice.","date":"2024","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/38653401","citation_count":23,"is_preprint":false},{"pmid":"28366809","id":"PMC_28366809","title":"Effect of D-Ala2GIP, a stable GIP receptor agonist on MPTP-induced neuronal impairments in mice.","date":"2017","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28366809","citation_count":23,"is_preprint":false},{"pmid":"32614526","id":"PMC_32614526","title":"The role of GLP-1/GIP receptor agonists in Alzheimer's disease.","date":"2020","source":"Advances in clinical and experimental medicine : official organ Wroclaw Medical University","url":"https://pubmed.ncbi.nlm.nih.gov/32614526","citation_count":22,"is_preprint":false},{"pmid":"33891864","id":"PMC_33891864","title":"Investigating GIPR (ant)agonism: A structural analysis of GIP and its receptor.","date":"2021","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/33891864","citation_count":21,"is_preprint":false},{"pmid":"32518064","id":"PMC_32518064","title":"GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in Hepatocyte Nuclear Factor 1α Mutation Carriers.","date":"2020","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/32518064","citation_count":21,"is_preprint":false},{"pmid":"38481208","id":"PMC_38481208","title":"Secretion of glucagon, GLP-1 and GIP may be affected by circadian rhythm in healthy males.","date":"2024","source":"BMC endocrine disorders","url":"https://pubmed.ncbi.nlm.nih.gov/38481208","citation_count":21,"is_preprint":false},{"pmid":"37379656","id":"PMC_37379656","title":"Combined GIP receptor and GLP1 receptor agonism attenuates NAFLD in male APOE∗3-Leiden.CETP mice.","date":"2023","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/37379656","citation_count":19,"is_preprint":false},{"pmid":"36551163","id":"PMC_36551163","title":"Evidence for Involvement of GIP and GLP-1 Receptors and the Gut-Gonadal Axis in Regulating Female Reproductive Function in Mice.","date":"2022","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/36551163","citation_count":19,"is_preprint":false},{"pmid":"39607493","id":"PMC_39607493","title":"GLP-1 and GIP agonism has no direct actions in human hepatocytes or hepatic stellate cells.","date":"2024","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/39607493","citation_count":18,"is_preprint":false},{"pmid":"36289848","id":"PMC_36289848","title":"Nephroprotective Properties of the Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists.","date":"2022","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/36289848","citation_count":18,"is_preprint":false},{"pmid":"37096236","id":"PMC_37096236","title":"Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes.","date":"2023","source":"Journal of diabetes research","url":"https://pubmed.ncbi.nlm.nih.gov/37096236","citation_count":18,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51373,"output_tokens":8186,"usd":0.138455,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18092,"output_tokens":4431,"usd":0.100617,"stage2_stop_reason":"end_turn"},"total_usd":0.239072,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"The human GIP receptor is a 466 amino acid seven-transmembrane domain G-protein coupled receptor that, when stably expressed in fibroblast CHL cells, couples to adenylate cyclase increasing intracellular cAMP (EC50 ~1.29×10⁻¹³ M for human GIP 1-42). The receptor accepts human GIP 1-42 and porcine GIP 1-30 as high-affinity ligands (Kd ~10⁻⁸ M) but shows no response to secretin, glucagon, GLP-1, VIP, PHI, or PACAP. GIP-1-42 stimulation did not increase intracellular calcium in transfected cells.\",\n      \"method\": \"Molecular cloning from human insulinoma cDNA library, stable transfection into CHL fibroblasts, radioligand binding assay, cAMP accumulation assay, intracellular calcium measurement\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution of receptor in heterologous cells with direct binding and functional cAMP assays, ligand specificity panel, calcium measurement\",\n      \"pmids\": [\"7589426\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"GIP (in the presence of insulin) increases LPL gene expression and LPL promoter activity in human adipocytes through a pathway involving PI3-K, PKB, and AMPK-dependent phosphorylation of CREB at Ser133 and nuclear localization of the CREB coactivator TORC2. CREB and TORC2 bind to a cAMP-response element (-II) in the human LPL promoter, and siRNA knockdown of either CREB or TORC2 reduces LPL expression. The cAMP/PKA pathway was not activated by GIP in the presence of insulin.\",\n      \"method\": \"LPL promoter-luciferase reporter assay in GIP receptor-expressing HEK-293 cells, phosphorylation assays, siRNA knockdown, chromatin immunoprecipitation, co-immunoprecipitation\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (reporter assay, ChIP, siRNA knockdown, co-IP) in a single rigorous study\",\n      \"pmids\": [\"20693566\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"A novel GIPR splice variant retaining intron 8 produces a C-terminally truncated GIPR. When co-expressed with wild-type GIPR in transfected cells, this truncated isoform does not produce cAMP in response to GIP but inhibits GIP-induced cAMP production through wild-type GIPR (dominant negative effect), coinciding with reduced wild-type GIPR cell-surface expression. In diet-induced obese mice, the ratio of truncated GIPR to total GIPR mRNA was reduced by ~32%, correlating with increased GIP-induced cAMP and insulin secretion (hypersensitivity).\",\n      \"method\": \"Transfection of truncated and wild-type GIPR constructs into cells, cAMP assay, cell surface receptor expression assay, RT-PCR in islets from HFD mice, ex vivo islet insulin secretion assay\",\n      \"journal\": \"American journal of physiology. Endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — heterologous expression with functional assays plus in vivo corroboration, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"17971513\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Each of the N-terminal extracellular Asn residues of the human GIP receptor is glycosylated when expressed in CHO cells. N-glycosylation enhances cell-surface expression and function of the GIPR more strongly than the GLP-1 receptor, primarily by reducing receptor degradation in the endoplasmic reticulum and lengthening receptor half-life. N-glycosylation is required for GIP receptor plasma membrane expression and efficient GIP-potentiated glucose-induced insulin secretion from INS-1 cells. Co-expression of a glycosylation-deficient GIP receptor mutant with wild-type GLP-1 receptor rescues its surface expression, and BRET data indicate formation of a GIP-GLP-1 receptor heteromer.\",\n      \"method\": \"Site-directed mutagenesis of Asn glycosylation sites, cell-surface expression assays, receptor half-life measurement, INS-1 insulin secretion assay, BRET\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — mutagenesis combined with functional assays (insulin secretion, surface expression) and BRET in a single study\",\n      \"pmids\": [\"22412906\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GIP(3-30)NH2 is a selective, efficacious GIPR antagonist in humans. In COS-7 cells it neither bound nor activated related receptors (GLP-1R, GLP-2R, glucagon R, secretin R, GHRH R). During hyperglycemic clamp in healthy men, co-infusion of GIP(3-30)NH2 reduced GIP-induced insulin secretion by 82% and returned glucose requirements to placebo levels. GIP(3-30)NH2 had no effect alone on glucagon, GLP-1, or lipid parameters.\",\n      \"method\": \"In vitro receptor binding and cAMP accumulation in transfected COS-7 cells; randomized double-blind crossover hyperglycemic clamp study in humans with co-infusion of GIP and GIP(3-30)NH2\",\n      \"journal\": \"Diabetologia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro receptor specificity panel plus rigorous randomized crossover clamp study in humans confirming functional antagonism\",\n      \"pmids\": [\"28948296\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PPARγ binds to a PPAR response element (PPRE) in the GIP receptor (GIP-R) promoter and regulates GIP-R transcription. Pancreas-specific PPARγ knockout mice show ~70% reduction in islet GIP-R protein. Thiazolidinedione activation of PPARγ in normal mouse islets causes ~3-fold increase in GIP-R protein and doubles insulin secretion in response to glucose+GIP. Hyperglycemia in ZF rats reduces both PPARγ and GIP-R protein, suggesting this pathway mediates GIP resistance in type 2 diabetes.\",\n      \"method\": \"Chromatin immunoprecipitation, siRNA, luciferase promoter assay in INS-1 cells, pancreas-specific PPARγ knockout mice, islet immunohistochemistry and protein expression\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — ChIP, siRNA, reporter assay, and genetic knockout model all supporting the same mechanistic conclusion\",\n      \"pmids\": [\"20332343\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Tirzepatide (dual GIP/GLP-1 receptor agonist) mimics native GIP at the GIP receptor but shows biased agonism at the GLP-1 receptor, favoring cAMP generation over β-arrestin recruitment, and produces weaker GLP-1 receptor internalization than native GLP-1. β-arrestin1 limits the insulin response to GLP-1 but not to GIP or tirzepatide in primary islets, suggesting that tirzepatide's GLP-1 receptor bias enhances insulin secretion. Receptor occupancy analysis shows greater engagement of tirzepatide at GIPR than GLP-1R at clinical doses.\",\n      \"method\": \"Receptor occupancy calculation, cAMP signaling assays, β-arrestin recruitment assays, receptor internalization assays, primary islet insulin secretion with β-arrestin1 manipulation\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — multiple in vitro signaling assays plus primary islet functional experiments in one rigorous study\",\n      \"pmids\": [\"32730231\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CNS GIPR signaling is required for the weight-reducing and food-intake-suppressing effects of GIP and GLP-1/GIP co-agonism. CNS-specific Gipr knockout mice and humanized GIPR knockin mice with CNS-hGIPR deletion on HFD show decreased body weight and improved glucose metabolism. Acute central and peripheral administration of acyl-GIP increases cFos neuronal activity in hypothalamic feeding centers, coinciding with decreased body weight and food intake. The superior metabolic effect of GLP-1/GIP co-agonism relative to GLP-1 is extinguished in CNS-Gipr KO mice.\",\n      \"method\": \"CNS-specific Gipr knockout mice, humanized GIPR knockin mice with CNS deletion, intracerebroventricular and peripheral administration of acyl-GIP, cFos immunohistochemistry, body weight and food intake measurements, epistasis with CNS-Gipr KO\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with CNS-specific KO combined with pharmacological and imaging approaches, replicated across multiple mouse models\",\n      \"pmids\": [\"33571454\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GIPR activation attenuates GLP-1R agonist-induced nausea and emesis while maintaining reduced food intake and body weight. Single-nuclei RNA sequencing of the area postrema/nucleus tractus solitarius (AP/NTS) identifies distinct neuronal populations expressing GIPR (predominantly GABAergic neurons) and GLP-1R (predominantly excitatory neurons). GIPR agonism in these GABAergic neurons blocks emetic and illness behaviors in multiple species.\",\n      \"method\": \"Behavioral pharmacology (emesis/nausea assays in mice, rats, musk shrews), single-nuclei RNA sequencing of AP/NTS, species comparison across three mammalian species\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — snRNA-seq cell-type identification combined with pharmacological loss-of-function in three species\",\n      \"pmids\": [\"34380697\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"GIP directly stimulates osteopontin (OPN) protein expression in a dose-dependent manner in rat primary adipocytes. A loss-of-function variant of GIPR (rs10423928) that reduces exon 9-containing receptor isoform (required for transmembrane activity) is associated with lower adipose tissue OPN mRNA and better insulin sensitivity in obese individuals.\",\n      \"method\": \"GIP treatment of primary rat adipocytes with OPN protein measurement, human genetic association of GIPR variant with adipose OPN mRNA and insulin sensitivity measures\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — direct in vitro stimulation assay plus human genetic data, but in vitro work done in rat adipocytes (not human) and genetic data is associative\",\n      \"pmids\": [\"23349498\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GIP directly reduces osteoclast activity through multiple signaling pathways (Src, cAMP, Akt, p38, NFκB) impairing nuclear translocation of NFATc1 and NFκB, inhibiting osteoclastogenesis, delaying bone resorption, and increasing osteoclast apoptosis in primary human osteoclasts. GIP also improves osteoblast survival. GIPR is robustly expressed in mature human osteoclasts (confirmed by RNA-seq and in situ hybridization). All effects are abolished by the GIPR antagonist GIP(3-30)NH2.\",\n      \"method\": \"Primary human osteoclast and osteoblast cultures, RNA-seq, in situ hybridization, LANCE cAMP assay, AlphaLISA phosphorylation assays, intracellular calcium imaging, confocal microscopy for NFATc1/NFκB localization, Seahorse bioenergetics, GIPR antagonist blockade\",\n      \"journal\": \"European journal of endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — primary human cells with multiple orthogonal signaling assays plus pharmacological blockade confirming GIPR mediation\",\n      \"pmids\": [\"36747334\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Using GIP(3-30)NH2, GIP receptor antagonism in healthy men reduces GIP-induced suppression of the bone resorption marker CTX by ~51% during hyperglycemic clamp, and attenuates GIP-stimulated P1NP (bone formation marker) and PTH suppression. These effects are GIPR-mediated.\",\n      \"method\": \"Randomized double-blind placebo-controlled crossover study, hyperglycemic clamp with GIP ± GIP(3-30)NH2 infusion, CTX and P1NP measurements\",\n      \"journal\": \"Bone\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — rigorous randomized crossover clamp study in humans with selective receptor antagonist confirming mechanism\",\n      \"pmids\": [\"31622777\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Endogenous GIP (during a mixed meal) contributes ~22–25% to postprandial suppression of bone resorption (CTX) in healthy humans, as demonstrated by GIPR antagonism with GIP(3-30)NH2. Endogenous GLP-1 had no detectable effect on bone resorption. Combined GIP and GLP-1 receptor antagonism additively impaired postprandial glycemic control and insulin secretion, indicating their effects on glucose homeostasis are additive. Only GIP affected gallbladder motility.\",\n      \"method\": \"Randomized double-blind placebo-controlled crossover study with four-arm design (GIP antagonist, GLP-1 antagonist, both, placebo) during OGTT and mixed meal test in healthy men\",\n      \"journal\": \"Bone / The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — rigorous randomized crossover human study with selective receptor antagonists, replicated across two meal types\",\n      \"pmids\": [\"32730920\", \"32077470\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Myeloid cell-specific GIPR deficiency in HFD-fed mice leads to greater weight gain, insulin resistance, hepatic steatosis, impaired energy expenditure, reduced WAT beiging, and myelopoiesis. GIP directly downregulates S100A8 expression in adipose tissue macrophages, and co-deletion of GIPR and S100A8/A9 in immune cells ameliorates the metabolic phenotype. This identifies a myeloid-GIPR-S100A8/A9 signaling axis coupling nutrient signals to inflammation and adaptive thermogenesis.\",\n      \"method\": \"Myeloid-specific Gipr knockout mice, HFD feeding, metabolic phenotyping, gene expression in WAT macrophages, direct GIP treatment of macrophages, genetic epistasis with S100A8/A9 co-deletion\",\n      \"journal\": \"Nature metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type specific KO, direct macrophage treatment, and genetic epistasis with co-deletion, multiple orthogonal methods\",\n      \"pmids\": [\"32694806\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GIPR is expressed in murine brown adipose tissue (BAT). GIP directly increases Il6 mRNA and IL-6 secretion in BAT cells. BAT-specific (Myf5 domain) Gipr knockout mice exhibit higher body temperature during acute cold challenge, lower respiratory exchange ratio, and impaired lipid tolerance at room temperature. At 4°C, GiprBAT-/- mice show lower body weight and higher iBAT oxygen consumption, indicating the BAT GIPR links to thermogenic fuel utilization and oxygen consumption.\",\n      \"method\": \"BAT cell culture with GIP treatment, siRNA knockdown of Gipr in BAT cells with gene expression, BAT-specific (GiprBAT-/-) knockout mice, metabolic cage phenotyping, cold challenge, ex vivo iBAT oxygen consumption\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — tissue-specific KO with functional phenotype, direct cell treatment, multiple metabolic readouts\",\n      \"pmids\": [\"31451430\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"β-arrestin 2 (ARRB2) mediates distinct roles in GLP-1R versus GIPR signaling in pancreatic β cells. For GIPR, ARRB2 is required for GIP-potentiated insulin secretion in both mouse and human islets. The GIPR-ARRB2 axis does not regulate cAMP/PKA or ERK signaling but mediates GIP-induced F-actin depolymerization. In contrast, for GLP-1R, ARRB2 dampens insulin secretion at physiological doses. The dual agonist tirzepatide does not require ARRB2 for insulin secretion potentiation.\",\n      \"method\": \"β-arrestin 2 knockout mouse islets, human islets with reduced ARRB2 (diabetogenic conditions), pharmacological assays for cAMP/PKA and ERK, F-actin staining, insulin secretion assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — genetic KO and direct signaling assays in both mouse and human islets, multiple orthogonal readouts\",\n      \"pmids\": [\"37897727\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Spatiotemporal analysis shows that GLP-1/GIP dual agonists MAR709 and tirzepatide induce diminished ligand-induced receptor internalization at both GIP and GLP-1 receptors compared to native agonists, while preserving maximal cAMP production despite partial Gαs recruitment. GLP-1R co-localization with Rab11-associated recycling endosomes was not different between MAR709 and GLP-1R mono-agonists.\",\n      \"method\": \"BRET-based Gαs recruitment and internalization assays, live-cell HILO microscopy for receptor trafficking, comparison across mono- and dual-agonists\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — BRET and live-cell microscopy provide quantitative receptor dynamics, multiple agonist comparisons\",\n      \"pmids\": [\"33556643\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GIP administered centrally (ICV) increases hypothalamic proinflammatory markers (Il-6, Socs3) and activates IκB kinase-β (IKKβ) inflammatory signaling. GIP also reduces anorectic insulin actions in the brain and diminishes insulin-induced phosphorylation of Akt and GSK3β in the hypothalamus. An antagonistic GIPR antibody and GIPR deficiency both significantly reduce proinflammatory cytokines and Socs3 in the hypothalamus during HFD feeding.\",\n      \"method\": \"ICV GIP administration in mice, unbiased RNA sequencing of GIP-stimulated hypothalami, GIPR antibody treatment, GIPR knockout mice, phospho-Akt and phospho-GSK3β Western blot, cytokine measurement\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple in vivo approaches with genetic and pharmacological loss-of-function, single lab\",\n      \"pmids\": [\"32603429\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"GIPR induction exclusively in adipocytes activates SERCA-mediated futile calcium cycling in white adipose tissue, increasing lipid oxidation, thermogenesis, and energy expenditure. Adipocyte-specific GIPR induction protects mice from diet-induced obesity and causes ~35% weight loss in obese mice. A 'metabolic memory' effect maintains weight loss after the transgene is switched off.\",\n      \"method\": \"Inducible adipocyte-specific GIPR transgenic mouse model, calcium flux assays, thermogenesis and energy expenditure measurement, body composition analysis, SERCA pathway interrogation\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — adipocyte-specific gain-of-function model with mechanistic identification of SERCA-mediated futile calcium cycling\",\n      \"pmids\": [\"39642881\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Long-acting GIPR agonism in human adipocytes and diet-induced obese mice: in the fed (insulin-present) state, GIPR agonism enhances insulin signaling, augments glucose uptake, and increases glucose-to-glycerol conversion cooperatively with insulin. In the fasted (insulin-absent) state, GIPR agonism increases lipolysis. In vivo, a long-acting GIPR agonist reduces circulating triglycerides during oral lipid challenge and increases lipoprotein-derived fatty acid uptake into adipose tissue.\",\n      \"method\": \"Human adipocyte functional assays (glucose uptake, glycerol production, lipolysis), DIO mouse model with long-acting GIPR agonist treatment, oral lipid challenge with triglyceride and fatty acid tracer measurement\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — human adipocyte assays plus in vivo DIO mouse model, multiple functional readouts across fed/fasted states\",\n      \"pmids\": [\"38878772\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GIP receptor agonism blocks emesis and attenuates illness behaviors (nausea surrogates) elicited by GLP-1R activation in mice, rats, and musk shrews, while maintaining GLP-1R agonist-induced reduction in food intake, body weight, and improved glucose tolerance. The area postrema/NTS of the hindbrain mediates these effects, and GIPR is most highly expressed in GABAergic neurons in this region.\",\n      \"method\": \"Multi-species pharmacological experiments (mice, rats, musk shrews), snRNA-seq of AP/NTS, GIPR agonist co-administration with GLP-1R agonists, food intake and emesis behavioral assays\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cross-species replication, snRNA-seq cell-type identification, pharmacological dissection of specific behaviors\",\n      \"pmids\": [\"34380697\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Structural and mutational analysis of the GIP receptor using a homology model of GIPR based on GLP-1R, combined with molecular dynamics and in vitro mutagenesis, identifies R183(2.60), R190(2.67), and R300(5.40) as key residues for GIPR activation. Disruption of a K293(ECL2)–E362(ECL3) salt bridge by GIPR antagonists strongly reduces GIPR activation. GIP(1-30)NH2 and GIP(1-42) have different binding modes compared with antagonists GIP(3-30)NH2 and GIP(5-30)NH2.\",\n      \"method\": \"Homology modeling, molecular dynamics simulation, in vitro site-directed mutagenesis with cAMP and binding assays\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — computational modeling validated by in vitro mutagenesis, single lab; homology model (not crystal structure) reduces tier\",\n      \"pmids\": [\"33891864\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Ectopic GIPR expression in adrenocortical adenomas causing GIP-dependent Cushing's syndrome occurs through monoallelic transcriptional activation of the GIPR gene. In some adrenal lesions, this is driven by somatic chromosomal duplications in the 19q13.32 region containing the GIPR locus, with rearrangements juxtaposing cis-acting regulatory sequences (including glucocorticoid response elements) to the translocated GIPR allele, driving its aberrant expression.\",\n      \"method\": \"Array-comparative genomic hybridization, RNA/DNA FISH, RRBS DNA methylation analysis, molecular analysis of adrenocortical lesions from 14 patients\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — molecular genomic analyses in patient tissue, multiple methods, but single center\",\n      \"pmids\": [\"28931750\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"GIP is rapidly inactivated primarily by N-terminal cleavage by dipeptidyl peptidase IV (DPP IV/CD26) on the cell surface of endothelial and epithelial cells, generating inactive metabolites. Cleavage by neprilysin (neutral endopeptidase) is a minor degradation route. Renal clearance eliminates incretin fragments but is of less importance for regulating incretin bioactivity.\",\n      \"method\": \"Biochemical degradation studies establishing DPP-IV as the primary inactivating enzyme (review synthesizing multiple mechanism studies)\",\n      \"journal\": \"Best practice & research. Clinical endocrinology & metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Strong — enzymatic mechanism well established across multiple prior studies; this paper synthesizes evidence rather than providing primary data\",\n      \"pmids\": [\"19748062\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Stimulating intestinal GIP release via chemogenetic activation (hM3Dq DREADD) of GIP-expressing K-cells in mice increases plasma GIP to postprandial levels and produces a robust inhibition of food intake. This anorectic effect is prevented by peripheral or central injection of antagonistic GIPR antibodies and reproduced when Dq expression is restricted to intestinal K-cells. The effect is maintained in diet-induced obese mice, with chronic K-cell activation reducing food intake and attenuating body weight gain.\",\n      \"method\": \"GIP-Dq DREADD mouse model, chemogenetic K-cell activation, peripheral and central GIPR antibody injection, intersectional Gip-Cre/Villin-Flp model, plasma GIP measurement, food intake and body weight assays\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — chemogenetic gain-of-function plus pharmacological blockade plus intersectional genetic model, multiple replications in same study\",\n      \"pmids\": [\"38653401\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"GLP-1-producing L-cells and GIP-producing K-cells rarely overlap (~5% co-expression) and differ by bombesin receptor-2 expression. Bombesin/neuromedin C stimulates GLP-1 but not GIP secretion, consistent with selective expression of the bombesin receptor-2 in L-cells but not K-cells, as demonstrated in isolated perfused mouse intestine and primary cultured intestinal cells.\",\n      \"method\": \"Transgenic mice with fluorescent markers in GIP-positive and GLP-1-positive cells, secretion assays in isolated perfused mouse intestine and primary cultured intestinal cells, expression analysis of bombesin receptor-2\",\n      \"journal\": \"The Journal of endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transgenic dual-reporter model plus functional secretion assays in native intestinal preparations\",\n      \"pmids\": [\"26483393\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"GLP-1R/GIPR agonists (liraglutide, acyl-GIP, and MAR709) have no direct actions in human hepatocytes or hepatic stellate cells at concentrations effective for insulin release. None reduced lipid content in oleic/palmitic acid-loaded hepatocytes, nor improved fibrotic marker expression in TGFβ-activated HSCs, nor induced CREB phosphorylation in either cell type.\",\n      \"method\": \"Human hepatocyte and HSC cell lines and primary cells treated with GLP-1R/GIPR agonists; lipid content assay, fibrotic marker expression, CREB phosphorylation assay\",\n      \"journal\": \"Cellular and molecular life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct cell treatment with multiple readouts in both cell lines and primary cells; finding is a negative result (no direct hepatocyte/HSC action)\",\n      \"pmids\": [\"39607493\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GIP (glucose-dependent insulinotropic polypeptide) is a 42-amino acid incretin hormone secreted by intestinal K-cells that acts through a seven-transmembrane Gαs-coupled receptor (GIPR), activating adenylate cyclase to raise intracellular cAMP and, in β-cells, stimulating glucose-dependent insulin secretion via PKA and β-arrestin 2-dependent pathways; N-glycosylation of the GIPR extracellular domain is required for its plasma-membrane expression and function; GIP is rapidly inactivated by DPP-IV cleavage; beyond the pancreas, GIP regulates adipocyte lipid metabolism (upregulating LPL transcription via PI3-K/PKB/AMPK-CREB/TORC2 and promoting fed-state glucose/lipid uptake while enhancing lipolysis when insulin is absent) through direct GIPR signaling, activates SERCA-mediated futile calcium cycling in adipocytes to increase energy expenditure, suppresses bone resorption by inhibiting osteoclastogenesis via Src/cAMP/Akt/NFκB/NFATc1 pathways in primary human osteoclasts, modulates hypothalamic inflammation and insulin resistance through CNS GIPR signaling, attenuates GLP-1-induced nausea/emesis via hindbrain GABAergic neurons, and downregulates S100A8/A9 in myeloid cells to restrain adipose inflammation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"GIP (glucose-dependent insulinotropic polypeptide) is an intestinal incretin hormone whose release from K-cells couples nutrient sensing to systemic metabolic, skeletal, and central control through its dedicated seven-transmembrane Gαs-coupled receptor GIPR, which raises intracellular cAMP upon ligand binding and discriminates GIP from related secretin-family peptides [#0]. Within pancreatic β-cells GIPR potentiates glucose-induced insulin secretion, a response requiring N-glycosylation of the receptor's extracellular domain for plasma-membrane expression and receptor stability [#3], and dependent on β-arrestin 2, which mediates GIP-induced F-actin depolymerization without engaging cAMP/PKA or ERK [#15]; GIPR transcription is itself controlled by PPARγ acting at a promoter PPRE, linking adipokine signaling to incretin sensitivity [#5]. Beyond the pancreas, GIP acts directly on adipocytes to drive insulin-cooperative glucose uptake and fed-state lipid storage while promoting fasting-state lipolysis [#19] and, through adipocyte GIPR, activates SERCA-mediated futile calcium cycling that increases thermogenesis and energy expenditure [#18]; in primary human osteoclasts it suppresses osteoclastogenesis and bone resorption via Src/cAMP/Akt/NFκB/NFATc1 signaling [#10], a function confirmed in humans where GIPR antagonism reverses GIP-driven suppression of bone resorption [#11, #12]. Central GIPR signaling is required for the weight-reducing and anorectic effects of GIP and GLP-1/GIP co-agonism [#7], and GIPR-expressing GABAergic neurons in the area postrema/NTS mediate suppression of GLP-1R-agonist-induced nausea and emesis [#8, #20]. GIP is rapidly inactivated by N-terminal cleavage by DPP-IV [#23], and selective antagonism with GIP(3-30)NH2 establishes the receptor's causal role in insulin secretion and bone resorption in humans [#4]. Pharmacologically, dual GIP/GLP-1 agonists such as tirzepatide mimic native GIP at GIPR while showing biased, internalization-sparing agonism at GLP-1R [#6, #16].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Establishing the molecular identity and signaling output of the GIP receptor answered how GIP transduces its hormonal signal, defining it as a Gαs-coupled GPCR specific for GIP.\",\n      \"evidence\": \"Molecular cloning from human insulinoma cDNA, stable expression in CHL fibroblasts, radioligand binding and cAMP assays with a secretin-family specificity panel\",\n      \"pmids\": [\"7589426\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structural model of ligand engagement at this stage\", \"Calcium signaling absent in fibroblasts but not tested in native cell types\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Discovery of a dominant-negative truncated GIPR splice variant explained how receptor surface availability is tuned and linked isoform balance to GIP sensitivity in obesity.\",\n      \"evidence\": \"Co-expression of truncated and wild-type GIPR with cAMP and surface-expression assays, RT-PCR and islet secretion in diet-induced obese mice\",\n      \"pmids\": [\"17971513\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of reduced surface expression of wild-type receptor not resolved\", \"Human relevance of the splice variant ratio not established\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defining PPARγ control of GIPR transcription and the GIP-driven LPL induction pathway connected receptor expression and adipocyte lipid handling to nuclear regulatory programs.\",\n      \"evidence\": \"ChIP, siRNA, luciferase reporters in INS-1 cells, pancreas-specific PPARγ KO mice; and LPL promoter reporter, ChIP, siRNA and co-IP in GIPR-expressing cells\",\n      \"pmids\": [\"20332343\", \"20693566\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether insulin-context switching between cAMP/PKA and PI3-K/PKB pathways occurs in vivo unresolved\", \"Direct demonstration of PPARγ-GIPR axis driving human GIP resistance not shown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identifying N-glycosylation of the GIPR extracellular domain answered why receptor surface expression and insulinotropic function depend on post-translational processing, and uncovered GIP-GLP-1 receptor heteromerization.\",\n      \"evidence\": \"Site-directed mutagenesis of Asn sites, surface expression and half-life assays, INS-1 insulin secretion, and BRET\",\n      \"pmids\": [\"22412906\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of the GIP-GLP-1 heteromer in native cells unknown\", \"Whether glycosylation is dynamically regulated not addressed\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Development of the selective antagonist GIP(3-30)NH2 enabled causal interrogation of GIPR in humans, proving GIP's dominant contribution to glucose-stimulated insulin secretion; and ectopic GIPR genomics explained GIP-dependent Cushing's syndrome.\",\n      \"evidence\": \"Receptor specificity panel in COS-7 cells plus randomized crossover hyperglycemic clamp in healthy men; and aCGH, FISH and methylation analysis of adrenocortical lesions\",\n      \"pmids\": [\"28948296\", \"28931750\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Single-center genomic analysis of adrenal lesions\", \"Antagonist effects on non-pancreatic tissues not yet mapped at this stage\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Establishing direct GIP action in primary human osteoclasts and confirming it with human antagonist studies answered how GIP couples nutrient intake to skeletal homeostasis.\",\n      \"evidence\": \"Primary human osteoclast/osteoblast cultures, RNA-seq, signaling and bioenergetics assays with GIPR antagonist; and randomized crossover clamp with GIP ± GIP(3-30)NH2 measuring CTX/P1NP\",\n      \"pmids\": [\"36747334\", \"31622777\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Long-term skeletal consequences of GIP signaling not established\", \"Relative contribution of each signaling arm (Src/cAMP/Akt/NFκB) not quantified\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Tissue-specific GIPR deletion in brown adipose tissue and myeloid cells revealed peripheral GIPR roles in thermogenic fuel use and adipose inflammation beyond the pancreas.\",\n      \"evidence\": \"BAT-specific and myeloid-specific Gipr knockout mice with metabolic phenotyping, direct cell treatment, and genetic epistasis with S100A8/A9 co-deletion\",\n      \"pmids\": [\"31451430\", \"32694806\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the myeloid-GIPR-S100A8/A9 axis operates in humans unknown\", \"Reconciliation of GIPR agonism versus deficiency both yielding metabolic benefit unresolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Quantifying the endogenous incretin contribution to postprandial physiology and characterizing tirzepatide's biased agonism clarified GIP's physiological footprint and the pharmacology of dual agonists.\",\n      \"evidence\": \"Four-arm randomized antagonist crossover study in healthy men; and receptor occupancy, cAMP, β-arrestin and internalization assays with primary islet secretion\",\n      \"pmids\": [\"32730920\", \"32077470\", \"32730231\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of additive glucose effects of GIP and GLP-1 not molecularly dissected\", \"Tissue selectivity of tirzepatide engagement at clinical doses incompletely mapped\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defining CNS and hindbrain GIPR functions answered how central GIPR signaling mediates weight loss, food-intake suppression, hypothalamic inflammation, and protection from GLP-1-induced nausea.\",\n      \"evidence\": \"CNS-specific and humanized Gipr knockout mice with cFos imaging; snRNA-seq of AP/NTS with multi-species behavioral pharmacology; ICV GIP with RNA-seq, antibody and KO loss-of-function; and structural homology modeling with mutagenesis\",\n      \"pmids\": [\"33571454\", \"34380697\", \"32603429\", \"33891864\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Crystal/cryo-EM structure of GIPR-ligand complex not available (homology model only)\", \"Mechanism linking GABAergic GIPR neurons to anti-emetic output not resolved\", \"CNS hypothalamic inflammation findings are single-lab and Medium confidence\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Dissecting β-arrestin 2 dependence distinguished GIPR from GLP-1R signaling logic, showing ARRB2 is required for GIP-potentiated insulin secretion via F-actin remodeling rather than cAMP.\",\n      \"evidence\": \"β-arrestin 2 knockout mouse islets and ARRB2-reduced human islets with cAMP/PKA, ERK, F-actin and insulin secretion assays\",\n      \"pmids\": [\"37897727\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular link between ARRB2 and F-actin depolymerization not defined\", \"Relevance to non-islet GIPR-expressing tissues untested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Adipocyte and K-cell gain-of-function models, fed/fasted adipocyte pharmacology, and a hepatocyte negative-control study refined where GIPR agonism acts to drive weight loss and energy expenditure.\",\n      \"evidence\": \"Inducible adipocyte-specific GIPR transgenic mice with SERCA calcium cycling analysis; chemogenetic K-cell activation with GIPR antibody blockade; human adipocyte fed/fasted functional assays plus DIO mouse lipid challenge; and direct GLP-1R/GIPR agonist treatment of human hepatocytes/HSCs\",\n      \"pmids\": [\"39642881\", \"38653401\", \"38878772\", \"39607493\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of the 'metabolic memory' weight-loss persistence unknown\", \"Whether intestinal K-cell-driven anorexia operates in humans untested\", \"Hepatic absence of effect is a negative result requiring dose/context boundaries\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How GIPR agonism and GIPR loss-of-function can both yield metabolic benefit, and the high-resolution structural basis of agonist versus antagonist binding, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No experimental atomic structure of the GIPR-ligand complex\", \"Reconciliation of agonist-vs-antagonist metabolic benefit paradox unresolved\", \"Human translation of CNS and adipocyte mouse mechanisms incomplete\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 4, 6]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [3, 0]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [23, 24]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 6, 15]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [18, 19, 14]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"GIPR\", \"DPP4\", \"GLP1R\", \"ARRB2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}